Skip to content

Soothing and Re-epithelizing Activity of New Cosmetic Formulations in Comparison to Placebo and Untreated Control Area

Soothing and Re-epithelizing Activity of New Cosmetic Formulations in Comparison to Placebo and Untreated Control Area

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03464890
Enrollment
20
Registered
2018-03-14
Start date
2018-01-22
Completion date
2018-02-13
Last updated
2018-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sensitive Skin

Brief summary

Open clinical study to evaluate the soothing and re-epithelizing activity of a single application of two cometic formulations (P926 - LICHTENA DermAD CREMA VISO and P927 - LICHTENA DermAD CREMA CORPO) on experimentally induced erythema by repeated tape stripping on the forearm (volar surface) of 20 healthy volunteers. Study products activity was assessed in comparison to placebo (P926P - LICHTENA DermAD CREMA VISO - PLACEBO) and versus untreated control area.

Interventions

OTHERP926 - LICHTENA DermAD CREMA VISO

The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.

The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.

OTHERP926 - LICHTENA DermAD CREMA VISO - PLACEBO

The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.

OTHERUntreated control area

Untreated skin area of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.

Sponsors

Derming SRL
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Volunteers of both sexes * TEWL value on tested skin areas immediately after tape stripping \>15g/m2-h * volunteers in a good general state of health in the Investigator opinion * volunteers not taking drugs or undergoing surgical procedure * volunteers who are giving a written informed consent.

Exclusion criteria

* Pregnancy (only for female subjects) * lactation (only for female subjects) * TEWL value on tested skin areas immediately after tape stripping \<15g/m2-h * change in the normal habits in the last month * participation in a similar study during the previous month * known allergy to one or several ingredients of the products on trial. * Dermatitis * presence of cutaneous disease on the tested area, as lesions, scars, malformations * clinical and significant skin condition on the test area. * Diabetes * endocrine disease * hepatic disorder * renal disorder * cardiac disorder * pulmonary disease * cancer * neurological or psychological disease * inflammatory/immunosuppressive disease * drug allergy. * Anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago); * using of drugs able to influence the test results in the investigator opinion.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline of skin erythema indexBaseline (T0), 1 hour (T1h), 24 hours (T24h)The instrumental measurement of erythema is performed by the use of an optical densitometer (X-RITE 404)
Change from baseline of skin rednessBaseline (T0), 1 hour (T1h), 24 hours (T24h)The instrumental measurement of skin redness is performed by the use of an optical colorimetry (Chroma Meter CR-200®)
Change from baseline of Transepidermal water loss (TEWL)Baseline (T0), 1 hour (T1h), 24 hours (T24h)The measurement of TEWL, performed by the use of Tewameter® TM300, allows to objectively monitor skin responses to cosmetic treatments. A shift from low-normal rates of TEWL to high levels is due to barrier disruption.
Change from baseline of Superficial skin hydrationBaseline (T0), 1 hour (T1h), 24 hours (T24h)Skin electrical capacitance value is measured with Corneometer CM825
Change from baseline of deep skin hydrationBaseline (T0), 1 hour (T1h), 24 hours (T24h)Tissue dielectric constant of deep skin layers is measured with MoistureMeterD
Change from baseline of Epicutaneous pHBaseline (T0), 1 hour (T1h), 24 hours (T24h)Surface cutaneous pH is measured with pH meter HI5221
Change from baseline of Surface microrelief's regularityBaseline (T0), 1 hour (T1h), 24 hours (T24h)Surface microrelief's regularity is performed on skin replicas images acquired by Primos compact portable

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026